Asked by: Julian Smith (Conservative - Skipton and Ripon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 March 2025 to Question 36392, if he will provide an update on funding for lobular breast cancer research.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises the crucial need for research into all forms of cancer, including lobular breast cancer. We remain committed to the role of research in driving a stronger collective understanding of the biology behind lobular breast cancer and to improve outcomes for women.
Government responsibility for delivering cancer research is shared between Department for Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation, which includes the Medical Research Council.
In November 2025, the NIHR issued a highlight notice encouraging applications for new research into lobular breast cancer, to improve the detection, diagnosis, treatment, and long-term surveillance of patients.
The NIHR continues to welcome high quality funding applications for research into any aspect of human health and care, including lobular breast cancer.
Asked by: Mims Davies (Conservative - East Grinstead and Uckfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that 85 per cent of breast cancer patients start treatment within 62 days of urgent referral.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Cancer patients are waiting too long for diagnosis and treatment, and improving performance against cancer waiting time standards, including the 62-day standard, is a priority for the Government.
It is a priority for the Government to support the National Health Service to diagnose cancer, including breast cancer, as early and quickly as possible, and to treat it faster, to improve outcomes for patients across England. The Department is committed to improving waiting times for cancer treatment so that people with cancer can access the care they need more quickly.
We are committed to transforming diagnostic services and will support the NHS to increase capacity to meet demand through investment in new diagnostic capacity, including magnetic resonance imaging and computed tomography scanners. As a first step towards earlier diagnosis and faster treatment, the NHS is now delivering an extra 40,000 operations, scans and appointments each week.
In May 2025, NHS England announced the world’s first roll out of liquid biopsy testing, which is now available for all eligible breast cancer patients, and which aims to speed up diagnosis and inform better treatment options for those with breast cancer.
£70 million has been invested into new LINAC radiotherapy machines, to replace older, less efficient machines. This vital investment demonstrates our commitment to improving radiotherapy services, and will ensure that the most advanced treatments are available to patients who need it and will boost productivity, reducing waiting lists and ultimately improving outcomes.
The upcoming National Cancer Plan will include further details on how we will improve outcomes for cancer patients, as well as speeding up diagnosis and treatment. It will ensure that patients have access to the latest treatments and technology and bring cancer care back into communities which need it the most. The plan will be published early this year.
Asked by: Mims Davies (Conservative - East Grinstead and Uckfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when NHS England will publish the delayed breast screening uptake improvement plan.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England will publish a Breast Screening Programme Uptake Improvement Review this year, to help improve uptake and address inequalities.
The review supports breast screening service providers with national solutions such as:
Asked by: Julian Smith (Conservative - Skipton and Ripon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the current age limits for routine breast cancer screening; and whether he plans to review these limits to improve early detection for patients outside of the standard screening range.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is guided by the UK National Screening Committee (UK NSC), an independent scientific advisory committee which makes its recommendations based on internationally recognised criteria and a rigorous evidence review and consultation process. It is only where the committee is confident that screening would provide more good than harm that a screening programme is recommended, as all medical interventions carry an inherent risk.
The NHS Breast Screening Programme (NHS BSP) offers all women in England between the ages of 50 to 71 years old the opportunity to be screened every three years for breast cancer, to help detect abnormalities and intervene early to reduce the number of lives lost to invasive breast cancer.
The AgeX research trial has been looking at the effectiveness of offering some women one extra screen between the ages of 47 to 49 years old, and one between the ages of 71 to 73 years old. The biggest trial of its kind ever to be undertaken, AgeX will provide robust evidence about the effectiveness of screening in these age groups, including the benefit and harms. The UK NSC will review the publication of the age extension trial when it reports.
Women with a very high risk of breast cancer, for example due to family history, may be offered screening earlier and more frequently, sometimes using magnetic resonance imaging rather than a mammogram.
While the NHS BSP does not automatically invite women for breast screening after their 71st birthday, women aged 71 years old or over can still have breast screening every three years if they want to, by calling their local breast screening service to ask for an appointment.
Asked by: Julian Smith (Conservative - Skipton and Ripon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that local cancer treatment facilities, such as mobile chemotherapy units and hospital breast cancer clinics, have sufficient resources to meet demand and reduce waiting times for patients.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
As set out in the plan for reforming elective care, the Government is committed to improving performance on cancer waiting times.
To improve access to cancer treatment, the Government is investing an extra £26 billion in the National Health Service and providing it with the resources it needs, including community diagnostic centres, to ensure patients are diagnosed faster and earlier so that they receive timely access to treatment. £70 million will also be spent on replacing out-of-date radiotherapy equipment so that cancer patients benefit from faster and safer cancer treatment using the most up-to-date technology. Replacing these older machines will save as many as 13,000 appointments from being lost to equipment breakdown.
NHS England has partnered with the charity Hope For Tomorrow to establish mobile chemotherapy units across England, bringing chemotherapy and cancer treatments closer to patients' homes, reducing waiting time for hospital appointments, with units staffed by specialist nurses offering personalised care.
The NHS has made important progress on the treatment of cancer, including breast cancer, delivering an extra 40,000 operations, scans, and appointments each week to ensure faster treatment for those who need it most.
Asked by: Amanda Hack (Labour - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of targeted interventions to improve breast cancer screening uptake among underserved groups.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The NHS Breast Screening Programme (NHSBSP) has returned to normal operation following disruption from COVID-19 and subsequent recovery measures.
NHSBSP is seeing improvement in uptake nationally with annual data for 2023/24 showing the number of women who are up to date with their screening has increased to the highest on record, to 4.61 million.
Breast screening uptake among those invited in 2023/24 improved to 70%, an increase from 64.6% in 2022/23, which is the first time the NHSBSP has hit its acceptable target for breast screening uptake since before the pandemic.
In February 2025, NHS England launched the first ever National Health Service breast screening campaign nationally to widespread media attention. It ran across television, radio, social media, and outdoor advertising during February and March, targeting women of breast screening age, with a focus on those least likely to attend, including younger women, those in deprived areas, ethnic minorities, and disabled women.
Specifically, regarding North West Leicestershire, measures to improve uptake include implementation of a timed appointment system which gives patients a specific date and time for their screening appointment, rather than asking them to contact the service to arrange one themselves. Evidence has shown that timed appointments improve participation and help reduce health inequalities. In addition, workforce structure is being reviewed to ensure a resilient staffing establishment capable of managing the higher demand from the timed appointment system.
More broadly, the integrated care board works with NHS England to support an increase in breast screening across Leicester, Leicestershire, Rugby. This includes:
Asked by: Amanda Hack (Labour - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the backlog and other impacts of the Covid-19 pandemic on the breast cancer screening programme has been completed.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The NHS Breast Screening Programme (NHSBSP) has returned to normal operation following disruption from COVID-19 and subsequent recovery measures.
NHSBSP is seeing improvement in uptake nationally with annual data for 2023/24 showing the number of women who are up to date with their screening has increased to the highest on record, to 4.61 million.
Breast screening uptake among those invited in 2023/24 improved to 70%, an increase from 64.6% in 2022/23, which is the first time the NHSBSP has hit its acceptable target for breast screening uptake since before the pandemic.
In February 2025, NHS England launched the first ever National Health Service breast screening campaign nationally to widespread media attention. It ran across television, radio, social media, and outdoor advertising during February and March, targeting women of breast screening age, with a focus on those least likely to attend, including younger women, those in deprived areas, ethnic minorities, and disabled women.
Specifically, regarding North West Leicestershire, measures to improve uptake include implementation of a timed appointment system which gives patients a specific date and time for their screening appointment, rather than asking them to contact the service to arrange one themselves. Evidence has shown that timed appointments improve participation and help reduce health inequalities. In addition, workforce structure is being reviewed to ensure a resilient staffing establishment capable of managing the higher demand from the timed appointment system.
More broadly, the integrated care board works with NHS England to support an increase in breast screening across Leicester, Leicestershire, Rugby. This includes:
Asked by: Amanda Hack (Labour - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how he plans to support areas with lower than national average attendance to breast cancer screening appointments, such as North West Leicestershire.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The NHS Breast Screening Programme (NHSBSP) has returned to normal operation following disruption from COVID-19 and subsequent recovery measures.
NHSBSP is seeing improvement in uptake nationally with annual data for 2023/24 showing the number of women who are up to date with their screening has increased to the highest on record, to 4.61 million.
Breast screening uptake among those invited in 2023/24 improved to 70%, an increase from 64.6% in 2022/23, which is the first time the NHSBSP has hit its acceptable target for breast screening uptake since before the pandemic.
In February 2025, NHS England launched the first ever National Health Service breast screening campaign nationally to widespread media attention. It ran across television, radio, social media, and outdoor advertising during February and March, targeting women of breast screening age, with a focus on those least likely to attend, including younger women, those in deprived areas, ethnic minorities, and disabled women.
Specifically, regarding North West Leicestershire, measures to improve uptake include implementation of a timed appointment system which gives patients a specific date and time for their screening appointment, rather than asking them to contact the service to arrange one themselves. Evidence has shown that timed appointments improve participation and help reduce health inequalities. In addition, workforce structure is being reviewed to ensure a resilient staffing establishment capable of managing the higher demand from the timed appointment system.
More broadly, the integrated care board works with NHS England to support an increase in breast screening across Leicester, Leicestershire, Rugby. This includes:
Asked by: Mims Davies (Conservative - East Grinstead and Uckfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce delays caused by inadequate clinic capacity that prevent urgent breast referrals from meeting the 28 day Faster Diagnosis Standard.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is supporting the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new magnetic resonance imaging and computed tomography scanners. The Government is investing an extra £26 billion in the NHS over two years and is opening up community diagnostic centres at evening and weekends, to help catch cancer earlier, including breast cancer.
To ensure that those with signs and symptoms that may indicate breast cancer have cancer diagnosed or ruled out as quickly as possible, NHS England has published guidance for local systems on implementing a timed breast cancer diagnostic pathway. The guidance sets out how diagnosis within 28-days can be achieved for the suspected breast cancer pathway in line with Faster Diagnosis Standard.
Asked by: Mims Davies (Conservative - East Grinstead and Uckfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that people living with incurable secondary breast cancer have timely access to new and effective medicines, including treatments such as Enhertu and Trodelvy.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body that makes recommendations on whether new licensed medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness.
NICE has recommended Enhertu, also named trastuzumab deruxtecan, for use in the Cancer Drugs Fund for the treatment of women with HER2-positive secondary breast cancer and it is now available for the treatment of eligible patients while further data on its effectiveness is being collected that will inform a NICE decision on routine funding. NICE did not recommend Enhertu for the treatment of HER-2 low metastatic and unresectable breast cancer as a clinically and cost-effective use of NHS resources.
NICE terminated its appraisal of Trodelvy, also named sacituzumab govitecan, for treating hormone receptor-positive HER2-negative metastatic breast cancer after two or more treatments in August 2025, as the company, Gilead, did not provide an evidence submission.